We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Advisory Committees Back Egalet's Opioid Arymo With Abuse-Deterrent Labels
FDA Advisory Committees Back Egalet's Opioid Arymo With Abuse-Deterrent Labels
Two FDA advisory committees recommend the approval of Egalet's opioid Arymo to manage severe pain that requires daily, long-term treatment when alternatives are unavailable, with three abuse-deterrent labels.